ID
45669
Descripción
Principal Investigator: Andy Futreal, PhD, UT MD Anderson Cancer Center, Houston, TX, USA MeSH: Melanoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001257 Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-γ, which is a critical cytokine for host immune responses. However, the role of IFN-γ signaling in tumor cells in the setting of anti-CTLA-4 therapy remains unknown. Here we demonstrate that, based upon exome sequencing data, patients identified as non-responders to anti-CTLA-4 (ipilimumab) harbor a much higher genomic defects in the IFN-γ pathway genes than melanoma patients who had clinical response to ipilimumab therapy.
Link
Palabras clave
Versiones (1)
- 2/4/23 2/4/23 - Simon Heim
Titular de derechos de autor
Andy Futreal, PhD, UT MD Anderson Cancer Center, Houston, TX, USA
Subido en
2 de abril de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs001257 Genetic Analysis of Tumor Samples
The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for melanoma tumor.
- StudyEvent: SEV1
- The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for melanoma tumor.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject IDs, response upon anti-CTLA4 treatment or IFNgamma-stimulation, sex, and disease onset age.
- This sample attributes table contains sample IDs, sample type, analyte type, tumor status, histological type, tumor treatment, and name of the center which conducted sequencing.
Similar models
The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for melanoma tumor.
- StudyEvent: SEV1
- The subject consent file includes subject IDs, consent information, subject aliases, and affection status of the subject for melanoma tumor.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject IDs, response upon anti-CTLA4 treatment or IFNgamma-stimulation, sex, and disease onset age.
- This sample attributes table contains sample IDs, sample type, analyte type, tumor status, histological type, tumor treatment, and name of the center which conducted sequencing.
C0441833 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,2])
C0681850 (UMLS CUI [1,3])
C3847505 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,3])